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Abstract 
Athletic pre-participation cardiac screening including electrocardiogram (ECG) is a subject of 
controversy among sports medicine practitioners. Opponents of pre-participation ECG screening 
cite concerns regarding the cost and accuracy of the testing. Recently, a single lead ECG 
accessory has become available for use with smartphones. The purpose of this study was to 
evaluate the between and within rater validity and reliability of the Kardia device in recording 
the ECG parameters rate, rhythm, and PR, QRS, QT intervals. The ECG parameters recorded 
with the smartphone were also compared to same measures made using a 12 lead 
electrocardiograph. 
This investigation used a repeated measures cross-sectional design. The investigation was 
conducted in two separate phases using separate participant samples. Phase 1 (N=10) was used to 
determine the within rater reliability with the Kardia device. Phase 2 (N=12) was used to 
determine the reliability between the Kardia device and the 12 lead electrocardiograph. 
The between rater and between device reliability for the rate, QT interval and QRS duration 
parameters ranged good to very good (ICC = 0.667 – 0.981). The current investigation showed 
that the reliability of the ECG parameters measured using the smartphone technology ranged 
from good to very good. This paper serves as support for a technological advancement that will 
help advance the debate on the utility of ECG testing as part of the athletic pre-participation 
physical. 
Keywords 
athletic pre-participation screening, smartphone application, Seattle Criteria, sudden cardiac 
death, electrocardiogram  
Introduction 
Sudden cardiac death (SCD) is an uncommon yet tragic problem that exists in competitive 
athletics. In the United States, the incidence of SCD amongst high school and collegiate athletes 
is estimated to be 1 in 200,000, with hypertrophic cardiomyopathy (HCM) the most common 
killer (36%).1 Approximately 5% of SCD are attributed to arrhythmias such as long QT 
syndrome (LQT), Wolff-Parkinson-White syndrome (WPW), and Brugada syndrome.1 
Identification of these electrical disorders in an athletic patient has been the topic of discussion 
amongst sports medicine physicians.    
The pre-participation cardiac screen including electrocardiogram (ECG) is a subject of 
controversy among sports medicine practitioners.2  Some sports medicine practitioners advocate 
that the benefits of pre-participation screening including ECG do not justify the risks of false 
positive test results leading to unnecessary additional workup and lost sport time.2 Opponents of 
mass ECG screening have their argument buttressed by studies that demonstrate the difficulty in 
consistent and correct interpretation of an athlete’s ECG, across interpreters of varying medical 
specialty and education.3 This can lead to a relatively high rate of false-positive interpretations 
and unnecessary secondary evaluations.3,4 
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A compelling contrary viewpoint based on evolving knowledge of ECG interpretation and its 
implementation in the athletic setting has been identified. A recent systematic review and meta-
analysis of fifteen papers (over 47,000 athletes) found ECG screening has a significantly higher 
sensitivity and a lower false positive rate than history or physical exam alone.5 To further 
strengthen the argument for the use of ECG in pre-participation screening there is opinion across 
many levels of sport internationally that the mass implementation of ECG has benefit for the 
athletic population.6 The increasing use of ECG in the pre-participation cardiac screening calls 
for improved agreement in the criteria used to interpret the ECG of the athlete.  
To improve ECG interpretation, the European Society of Cardiology (ESC) developed 
recommendations for physicians to use when analyzing the ECG of athletes.7 The ESC’s 
recommendations decreased the errors seen between physicians when interpreting the ECG of 
athletes.  
In 2013 the Seattle Criteria were developed with the hope to further decrease the variability of 
the ECG interpretations of athletes.8 The Seattle Criteria utilizes a checklist of findings to guide 
physicians in ECG interpretations.8 This checklist includes the same criteria as of the European 
Cardiology Society, as well as expands the guidelines for diagnosis of several electrical disorders 
of the heart. In 2014 the Refined Criteria created guidelines using a combination of the 
guidelines of European Cardiology Society and Seattle Criteria, and added some new boundaries.  
The frequency of abnormal ECG readings have decreased with the use of each criteria: European 
Cardiology Society 22%, Seattle Criteria 11.6%, Refined Criteria 5.3%.9 This demonstrates that 
Refined Criteria has had the most success in decreasing false positives in ECG interpretation by 
combining the most effective aspects of each criteria system and by standardizing interpretation 
techniques. 
More recently, a newer evaluation protocol has evolved. The International Criteria published in 
March 2017 is an amalgam of the best evidence to date.10 It has been endorsed by many 
governing bodies, including the American Medical Society for Sports Medicine, International 
Olympic Committee, European Society of Cardiology, and the American College of Cardiology.  
The International Criteria provides a consensus protocol from which those practicing within the 
field of cardiologic sports medicine should take direction. Among other items, it provides an 
algorithm for interpretation of ECG within the athletic subset defining findings as either 
“normal,” “abnormal,” or “borderline”. 
In light of the development of the International Criteria, reducing the burden associated with 
ECG collection and interpretation may be an effective strategy to make ECG screening more 
practical for application in athletic screening. This is especially important in the current sports 
medicine climate.  Due to unfortunate tragedy associated with undiagnosed arrhythmias and a 
perceived lack in resource utilization, it is the authors’ belief that it is incumbent upon physicians 
practicing within the athletic population to strongly consider the implementation of ECG 
screening during pre-participation physical examination.   
Smartphone based technology for ECG screening might further reduce the burden of mass ECG 
screening. Recently, a single lead ECG accessory (Kardia, AlivCore, San Francisco, CA) has 
become available for use with smartphones. This device is capable of recording a single lead 
ECG corresponding to leads I, II, or an anterior precordial lead depending on its placement upon 
the body. The application of this device in various populations and cardiac conditions has been 
investigated.11-18 The Kardia device could represent a cost-effective alternative to the standard 12 
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lead ECG in detecting life-threatening arrythmogenic pathology where a rhythm strip may be 
sufficient to detect pathology, such as WPW, LQT, Brugada, etc. The reduced cost and the 
increased ease of use of these devices will likely lead to an increase in the use of smartphone 
integrated ECG recording devices by sports medicine providers, in turn leading to greater 
variability in the level of medical training of the medical practitioner that are interpreting and 
applying the results of the ECG screening.  
The purpose of this investigation was to evaluate the validity and reliability of the Kardia device 
in measuring rate, rhythm, and the PR, QRS, and QT intervals on ECG strips collected using the 
Kardia device. We explored the consistency of the interpretation of the ECG amongst clinicians 
with varied training. The authors hypothesize that the Kardia device will perform comparably to 
a standard 12 lead ECG and that there will not be a statistically significant difference in the 
interpretation amongst clinicians beyond the accepted differences already acknowledged.  
Methods 
Three physicians participated in this investigation: a fellowship trained primary care sports 
medicine physician, a pediatric cardiologist, and a family medicine physician. Of these three 
physicians, two were well practiced and aware of the controversy and varying methods of ECG 
interpretation for the athletic subset.  The project was conducted in two phases. The goal of 
phase 1 was to determine the consistencies of the ECG measures within and between raters. 
Phase 2 determined the consistency of the ECG measures made between a smartphone ECG base 
device and a traditional 12 lead ECG in athletes. For phase 1 the ECG was collected from ten 
volunteers (8 male, 2 female); all were healthy and did not have a history of cardiac disease or 
injury. For phase 2 ECG data was collected from 12 healthy intercollegiate male basketball 
athletes of a similar age range to that of phase 1 group. All participants provided written 
informed consent prior to data collection procedures. The current study was approved by the 
Marshall University Internal Review Board (IRBNet ID# 826364-1).   
Phase 1  
The ECG signals were collected using the smartphone based Kardia (AliveCor Inc., San 
Francisco, CA, USA). One ECG strip was recorded from each participant, 2 copies of each strip 
were provided to each rater for interpretation. 
Phase 2  
The ECG signals were collected using 2 devices, the smartphone based Kardia and a traditional 
12 lead ECG device (Marquette Case 2, GE Medical Systems, Milwaukee, WI, USA). Raters 
were presented with 1 copy of the ECG strip from each device  
The ECG collection protocol was the same for both devices. The ECG signal was collected for 
60 seconds and analysis was performed on the middle 30 seconds of each ECG strip. Participants 
sat quietly for five minutes prior to the data collection.  Data from each device was collected 
following the manufacturer’s instructions by a clinician experienced and trained with the use of 
each device. All data was collected by the same investigator to ensure consistency. Following 
collection each ECG strip was identified by a coded identifier number. Lead 1 from the 12 lead 
and Kardia was used for analysis; lead 1 was chosen due to the ease of collection of lead 1 from 
the Kardia device. The identification of each ECG strip was removed and replaced by a random 
identifier prior to ECG analysis. Each rater analyzed all ECG strips. The ECG strips were 
presented to each rater in predetermined random order; random order was different for each 
64
Marshall Journal of Medicine, Vol. 4 [2018], Iss. 2, Art. 7
https://mds.marshall.edu/mjm/vol4/iss2/7
DOI: http://dx.doi.org/10.18590/mjm.2018.vol4.iss2.7
 
 
rater. All rater were blinded to any output other than the ECG tracing and the measurements 
made by the other raters. Each rater measured rate, rhythm and the PR, QRS, and QT intervals of 
all ECG strips. The ECG parameters were measured to the nearest millisecond using guidelines 
based on the rater’s specific training in ECG analysis. Raters recorded their measurements on 
paper data collection forms. Data was collated and entered into the database by the investigator 
that assigned the random identifier. Data analysis was performed by an investigator that was not 
active in the assessment in the ECG strips. 
Statistical Analysis 
The reliability of measures was determined using the Interclass Correlation coefficient (Model 2) 
for the continuous measures (rate, QT interval and QRS duration) and the Kappa statistic for the 
nominal data. Bland-Altman plots were produced in order to assess for systematic error.19 The 
difference between the first and second measurement for all continuous variables was calculated, 
a single sample t test was used to test if the differences were different than zero.  All statistical 
calculations were performed using SPSS 22 (SPSS, Chicago, IL), and statistical significance was 
determined at p<0.05. Intraclass correlation coefficients [ICC (2-way fixed)] was used to 
determine the inter-rater reliability of the continuous variables (rate, QT interval and QRS 
duration). The ICC value is  considered very good for values 0.81–1.00, good for 0.61–0.80, 
moderate for 0.41–0.60, fair for 0.21 – 0.40, and poor for values below 0.20.20 The kappa 
statistic greater than 0.80 is considered as representing excellent agreement, 0.60–0.79 
substantial agreement, 0.40–0.59 moderate agreement.20 Measurement error was calculated with 
the standard error of measure (SEM) = standard deviation x [√(1 - ICC)], which estimates the 
error about a single measure of a variable. The minimal detectable change (MDC) represents the 
error when a measure is taken twice (change over time), and was calculated by multiplying the 
SEM by the square root of 2.21,22 
Results 
Phase 1 
The between rater ICC for the heart rate showed excellent reliability (ICC = 0.981, 95%CI 0.955 
– 0.995) across the three raters. (Table 1)  
 
Table 1. Between rater measurement parameters, Phase 1 
Mean STD SEM MDC
Rate 71.6 11.7 1.6 2.3
PR interval 138 20.2 9.1 12.8
QRS interval 83 11.9 6.9 9.7
QT interval 352 25.8 11.8 16.7  
 
The between rater ICC for the PR (ICC = 0.798, 95%CI = 0.533 – 0.940), QRS (ICC = 0.667, 
95%CI = 0.287 – 0.897), and QT (ICC = 0.790, 95%CI = 0.509 – 0.938) intervals showed good 
reliability. The within rater ICC, SEM, and MDC values are presented in table 2.   
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Table 2. Within rater measurement parameters, Phase 1. 
1 2 3 1 2 3 1 2 3
Rate 0.916 0.983 0.948 3.0 1.4 3.1 4.2 2.0 4.4
PR interval 0.776 0.733 0.819 7.8 12.0 8.9 11.0 17.0 12.6
QRS interval 0.087 0.640 0.640 11.8 8.6 5.4 16.7 12.2 7.6
QT interval 0.653 0.344 0.946 14.3 24.4 5.4 20.2 34.5 7.6
ICC SEM MDC
 
 
Collapsed across all raters, the agreement of the cardiac rhythm between the 2 strips showed 
substantial agreement (kappa = 0.692, p < 0.01).  Individually the raters showed moderate to 
excellent agreement: rater 1 showed excellent agreement (kappa = 1.00, p = 0.01), rater 2 (kappa 
= 0.615, p = 0.03) and rater 3 (kappa = 0.583, p = 0.01) showed moderate agreement. Bland-
Altman plots (Figure 1) do not show a systematic bias with any of the parameter measures. The 
differences between the first and second measurements were not statistically different (p > 0.05) 
from zero for any of the parameters measured.  
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Figure 1. Bland-Altman plots for the repeated Alivcore measures, rate (top left), PR interval (top 
right), QRS interval (bottom left), QT (interval bottom right). 
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Phase 2 
The reliability of the measures between devices ranged from good to excellent (ICC = 0.678 – 
0.980).  The between device ICC values ranged from poor to excellent; ICC, SEM, and MCD are 
presented in table 3.   
 
Table 3. Between device measurements parameters, collapsed across raters Phase 2. 
12 Lead Alivecore 12 Lead Alivecore 12 Lead Alivecore 12 Lead Alivecore 12 Lead Alivecore
rate 62.7 61.8 11.2 12.5 0.944 0.979 2.7 1.8 3.7 2.6
PR interval 157 156 21 25 0.673 0.632 12.0 15.2 17.0 21.4
QRS interval 91.1 82.4 13.6 14 0.494 0.678 9.7 7.9 13.7 11.2
QT interval 392 387 41.5 30.1 0.777 0.583 19.6 19.4 27.7 27.5
Mean ICCSTD SEM MDC
 
 
 
The within rater ICC, SEM, and MDC values are presented in table 4.  
Table 4. Within rater measurement parameters, phase 2 
1 2 3 1 2 3 1 2 3
rate 0.952 0.951 0.882 2.8 3.0 3.2 3.9 4.2 4.5
PR internval 0.66 0.631 0.015 11.7 10.9 30.3 16.5 15.5 42.8
QRS interval 0.181 0.327 0.263 12.2 15.3 14.0 17.2 21.7 19.9
QT interval 0.868 0.919 0.182 13.1 8.2 38.7 18.5 11.6 54.7
ICC SEM MDC
 
 
Collapsed across all raters there was moderate agreement (kappa = 0.467, p < 0.01) for rhythm 
between the devices. The agreement for individual raters was varied; rater one showed poor 
agreement (kappa = 0.153, p = 0.40), rater two moderate agreement (kappa = 0.455, p = 0.02) 
while rater three rated all subjects as have a normal sinus rhythm based on the ECG strips 
collected from both devices. Visual evaluation of the Bland-Altman plots shows an apparent 
systematic bias for the rate and the PR interval. The difference in the rate measures (mean 
difference 2.1±4.7 bpm, t=-2.636, p = 0.01) and QRS interval (mean difference = 7.71±18.5ms, t 
= -469, p = 0.02) between the Kardia and 12 lead were statistically different from zero. The 
Kardia measurement was higher than the measurement made using the 12 lead, suggesting that 
the values were consistently overestimated when using the Kardia. The Bland-Altman plots 
(Figure 2) for the PR and QRS intervals showed a random distribution of the difference between 
the devices.  
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Figure 2. Bland-Altman plots for the between device comparisons, rate (top left), PR interval 
(top right), QRS interval (bottom left), QT (interval bottom right). 
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Discussion 
The current investigation showed that the reliability of the ECG parameters measured using the 
smartphone technology ranged from good to very good. When reliability within each clinician 
was explored the reliability decreased particularly for the QRS and QT interval measures.  None 
of the data analysis included QTc. With respect to QRS, it is reasonable to assert that this 
difference is due to the narrow measurement window. A difference of 0.05 milliseconds could 
skew data points widely.  It is important to note that none of the interpreters measured QT or 
QRS to be “abnormal”.  
The reliability of the ECG parameters between the devices ranged from fair to very good when 
calculated collapsed across the clinicians. The reliability decreased when calculated between the 
clinicians. The greatest decreases were found for the interval measures. The difference in the 
reliability amongst the clinicians may suggest that the clinician’s level of training and experience 
with interpreting ECG strips affects the consistency of these measurements. The systematic 
errors revealed in the rate and QRS interval measures between the two devices might also 
suggest that there are differences in the responsiveness of the devices. 
At the time of testing all participants were healthy with no known cardiac conditions. No 
abnormal findings were found during testing for the current study. The 95% confidence interval 
for all of the smartphone measured ECG parameters fell within the 95% confidence intervals for 
the published age based norms (Table 5).23 
 
Table 5. The 95% confedence intervals for age related normal values and values measured uisng 
the Kardia wirerless device.  
 
95% CI Norm Alivecor measure 95%CI SEM
rate 46 - 96 bpm 59 -65 bpm
PR interval 114 -193ms 138 - 174 ms
QRS interval 78 -118 ms 69 -96 ms
QT interval 341 - 455 ms 364 -410 ms  
 
No parameter measures exceeded the limits of European or Seattle Criteria. The results from the 
twelve basketball players would not produce false positive tests with respect to this single lead. 
This paper had many limitations. Given the small sample size of this investigation, readers must 
apply the results with caution. Stronger conclusions could be made if the investigation was 
duplicated utilizing larger sample sizes. Utilization of a single lead as a screening device during 
pre-participation examination is not an accepted practice nor one that is being advocated for by 
any medical body at the time of this writing. Even the most basic ECG screening requires 
multiple anatomical leads for analysis, not solely a rhythm strip.  It is the opinion of the authors 
that the use of the Kardia device is not to be advocated for in the pre-participation setting unless 
solely looking for the aforementioned arrythmogenic pathologies. The authors believe there is a 
definite role for its use in the on-field/athletic training clinic setting to rule out acute events such 
as arrhythmia. It is impossible to assert from the current investigation its efficacy in such a 
setting nor was it the intention of this study to do so.  
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Another limitation that was seen in this study echoes the known patterns of error associated with 
ECG interpretation.24 Discrepancies in interpretation were seen across the three subspecialties 
represented within the study.  Whether this is from the narrow measurement difference resulting 
in broad statistical difference, interpreter error, or variability within the smartphone device is 
unknown. The latter argument is made less likely by the fact that these problems are pervasive in 
the traditional ECG environment already.3 It is the opinion of the authors that the current study 
helps to validate the limited data this smartphone device is able to relay to the interpreter. 
The implementation of ECG screening within the athletic setting remains controversial.  The 
current investigation showed that the reliability of the ECG parameters measured using the 
smartphone technology ranged from good to very good. This paper serves as support for a 
technological advancement that will help advance the debate on the utility of ECG testing as part 
of the athletic pre-participation physical. Evolution in technology will continue to allow for 
arguments for and against the utility of pre-participation ECG screening.  This evolution of ECG 
technology may introduce new variables and create new quandaries.  The same trends seen in 
generally accepted means of pre-participation ECG screening can be seen within this study.23 
Further advancements in improvement in consistent interpreter quality, availability of measuring 
devices, and the reduction of burden associated with further work up following a positive ECG 
screen have been and remain necessary.   
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